Dasotraline

Dasotraline
Identifiers
	IUPAC name (1R,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine;
CAS Number	675126-05-3 ;
PubChem CID	9947999;
ChemSpider	8123611 ;
UNII	4D28EY0L5T;
KEGG	D10700 ;
ChEMBL	ChEMBL3301595;
CompTox Dashboard (EPA)	DTXSID20217855 ;
Chemical and physical data
Formula	C16H15Cl2N
Molar mass	292.20 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C[C@H](C2=CC=CC=C2[C@@H]1C3=CC(=C(C=C3)Cl)Cl)N;
	InChI InChI=1S/C16H15Cl2N/c17-14-7-5-10(9-15(14)18)11-6-8-16(19)13-4-2-1-3-12(11)13/h1-5,7,9,11,16H,6,8,19H2/t11-,16+/m0/s1; Key:SRPXSILJHWNFMK-MEDUHNTESA-N;
	(what is this?) (verify)

Dasotraline (INN;^[1] former developmental code name SEP-225,289) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that was under development by Sunovion for the treatment of attention-deficit hyperactivity disorder (ADHD) and binge eating disorder (BED).^[2]^[3]^[4]^[5] Structurally, dasotraline is a stereoisomer of desmethylsertraline (DMS), which is an active metabolite of the marketed selective serotonin reuptake inhibitor (SSRI) antidepressant sertraline (Zoloft).

^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 27 (4). WHO. 2013. Retrieved 4 November 2014.
^ Chen Z, Skolnick P (September 2007). "Triple uptake inhibitors: therapeutic potential in depression and beyond". Expert Opinion on Investigational Drugs. 16 (9): 1365–77. doi:10.1517/13543784.16.9.1365. PMID 17714023. S2CID 20271918.
^ DeLorenzo C, Lichenstein S, Schaefer K, Dunn J, Marshall R, Organisak L, et al. (July 2011). "SEP-225289 serotonin and dopamine transporter occupancy: a PET study". Journal of Nuclear Medicine. 52 (7): 1150–5. doi:10.2967/jnumed.110.084525. PMC 3856248. PMID 21680689.
^ Ziegler L, Küffer G, Euler E, Wilhelm K (August 1990). "[Arthrographic imaging of ganglions of the hand]" [Arthrographic imaging of ganglions of the hand]. RöFo (in German). 153 (2): 143–6. doi:10.1055/s-2008-1033352. PMID 2168068. S2CID 260312446.
^ Guiard B, Chenu F, El Mansari M, Blier P (2009). "P.1.c.059 Electrophysiological properties of the triple reuptake inhibitor SEP 225289 on monoaminergic neurons". European Neuropsychopharmacology. 19: S285. doi:10.1016/S0924-977X(09)70419-5. S2CID 54263757.